Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease
Purpose This trial is the first to compare directly the clinical response to and safety of oral and intravenous (IV) ibandronic acid for metastatic bone disease. Methods Patients ≥18 years with breast, prostate, lung, urogenital or colon cancer received IV ibandronic acid 6 mg infused over 15 min ev...
Gespeichert in:
| Veröffentlicht in: | Journal of cancer research and clinical oncology 2008-12, Vol.134 (12), p.1303-1310 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1310 |
|---|---|
| container_issue | 12 |
| container_start_page | 1303 |
| container_title | Journal of cancer research and clinical oncology |
| container_volume | 134 |
| creator | Mystakidou, Kyriaki Stathopoulou, Evangelia Parpa, Efi Kouloulias, Vassilios Kouskouni, Evangelia Vlahos, Lambros |
| description | Purpose
This trial is the first to compare directly the clinical response to and safety of oral and intravenous (IV) ibandronic acid for metastatic bone disease.
Methods
Patients ≥18 years with breast, prostate, lung, urogenital or colon cancer received IV ibandronic acid 6 mg infused over 15 min every 28 days or oral ibandronic acid 50 mg/day. Clinical response was determined using bone scintigraphy, radiography and serum C-terminal telopeptide of type I collagen (S-CTX) at months 3–6. Adverse events and biochemical safety measures were recorded.
Results
A total of 84.6 and 88.5% of patients had a complete/partial response to IV and oral ibandronic acid, respectively. Median percentage decreases in S-CTX were −39 and −35%, respectively. Bone pain scores decreased and analgesic use increased from month 0–3 and were stable from months 3–6. Both formulations improved physical and functioning scores.
Conclusion
Oral and IV ibandronic acid for bone metastases have similar efficacy and tolerability. |
| doi_str_mv | 10.1007/s00432-008-0419-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69714573</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19513668</sourcerecordid><originalsourceid>FETCH-LOGICAL-c430t-b23349d2ffb5343fbac92b133bf5f299882e9217e404a8ece773de59d187d8fb3</originalsourceid><addsrcrecordid>eNqFkU9rFTEUxYNY7Gv1A7iRINjdaP5OEneltCoUuqnrkGRuZMpM8kzySv325vEeFgRxleTmd-69h4PQW0o-UkLUp0qI4GwgRA9EUDM8vUAbuq9QzuVLtCFU0UEyOp6is1ofSH9LxV6hU6olESNlGxTvilvwI5S6q3hOrbhHSHl_9y5NJac5YBfm6TN2OOR168pcc8I54lbAtRVSw3nb5pwqjrngFZqrzbUu8zkBnuYKrsJrdBLdUuHN8TxH32-u76--Drd3X75dXd4OQXDSBs84F2ZiMXrJBY_eBcN8d-OjjMwYrRkYRhUIIpyGAErxCaSZqFaTjp6fo4tD323JP3dQm13nGmBZXILuyo5GUSEV_y9IjaR8HHUH3_8FPuRdSd2EZYxIokchO0QPUCi51gLRbsu8uvLLUmL3UdlDVLZHZfdR2aeueXdsvPMrTM-KYzYd-HAEXA1uicWlMNc_HCOacUVM59iBq_0r_YDyvOG_p_8GhQqstw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>220508645</pqid></control><display><type>article</type><title>Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Mystakidou, Kyriaki ; Stathopoulou, Evangelia ; Parpa, Efi ; Kouloulias, Vassilios ; Kouskouni, Evangelia ; Vlahos, Lambros</creator><creatorcontrib>Mystakidou, Kyriaki ; Stathopoulou, Evangelia ; Parpa, Efi ; Kouloulias, Vassilios ; Kouskouni, Evangelia ; Vlahos, Lambros</creatorcontrib><description>Purpose
This trial is the first to compare directly the clinical response to and safety of oral and intravenous (IV) ibandronic acid for metastatic bone disease.
Methods
Patients ≥18 years with breast, prostate, lung, urogenital or colon cancer received IV ibandronic acid 6 mg infused over 15 min every 28 days or oral ibandronic acid 50 mg/day. Clinical response was determined using bone scintigraphy, radiography and serum C-terminal telopeptide of type I collagen (S-CTX) at months 3–6. Adverse events and biochemical safety measures were recorded.
Results
A total of 84.6 and 88.5% of patients had a complete/partial response to IV and oral ibandronic acid, respectively. Median percentage decreases in S-CTX were −39 and −35%, respectively. Bone pain scores decreased and analgesic use increased from month 0–3 and were stable from months 3–6. Both formulations improved physical and functioning scores.
Conclusion
Oral and IV ibandronic acid for bone metastases have similar efficacy and tolerability.</description><identifier>ISSN: 0171-5216</identifier><identifier>EISSN: 1432-1335</identifier><identifier>DOI: 10.1007/s00432-008-0419-x</identifier><identifier>PMID: 18504612</identifier><identifier>CODEN: JCROD7</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject>Administration, Oral ; Aged ; Antineoplastic agents ; Biological and medical sciences ; Bone cancer ; Bone Density Conservation Agents - administration & dosage ; Bone Neoplasms - drug therapy ; Bone Neoplasms - secondary ; Bone Resorption - drug therapy ; Cancer Research ; Clinical trials ; Comparative studies ; Diphosphonates - administration & dosage ; Diseases of the osteoarticular system ; Drug delivery systems ; Drug therapy ; Female ; Hematology ; Humans ; Infusions, Intravenous ; Internal Medicine ; Male ; Medical sciences ; Medicine ; Medicine & Public Health ; Neoplasms - drug therapy ; Oncology ; Original Paper ; Osteoporosis. Osteomalacia. Paget disease ; Pharmacology. Drug treatments ; Prognosis ; Prospective Studies ; Quality of Life ; Tumors of striated muscle and skeleton</subject><ispartof>Journal of cancer research and clinical oncology, 2008-12, Vol.134 (12), p.1303-1310</ispartof><rights>Springer-Verlag 2008</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c430t-b23349d2ffb5343fbac92b133bf5f299882e9217e404a8ece773de59d187d8fb3</citedby><cites>FETCH-LOGICAL-c430t-b23349d2ffb5343fbac92b133bf5f299882e9217e404a8ece773de59d187d8fb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00432-008-0419-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00432-008-0419-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20823709$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18504612$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mystakidou, Kyriaki</creatorcontrib><creatorcontrib>Stathopoulou, Evangelia</creatorcontrib><creatorcontrib>Parpa, Efi</creatorcontrib><creatorcontrib>Kouloulias, Vassilios</creatorcontrib><creatorcontrib>Kouskouni, Evangelia</creatorcontrib><creatorcontrib>Vlahos, Lambros</creatorcontrib><title>Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease</title><title>Journal of cancer research and clinical oncology</title><addtitle>J Cancer Res Clin Oncol</addtitle><addtitle>J Cancer Res Clin Oncol</addtitle><description>Purpose
This trial is the first to compare directly the clinical response to and safety of oral and intravenous (IV) ibandronic acid for metastatic bone disease.
Methods
Patients ≥18 years with breast, prostate, lung, urogenital or colon cancer received IV ibandronic acid 6 mg infused over 15 min every 28 days or oral ibandronic acid 50 mg/day. Clinical response was determined using bone scintigraphy, radiography and serum C-terminal telopeptide of type I collagen (S-CTX) at months 3–6. Adverse events and biochemical safety measures were recorded.
Results
A total of 84.6 and 88.5% of patients had a complete/partial response to IV and oral ibandronic acid, respectively. Median percentage decreases in S-CTX were −39 and −35%, respectively. Bone pain scores decreased and analgesic use increased from month 0–3 and were stable from months 3–6. Both formulations improved physical and functioning scores.
Conclusion
Oral and IV ibandronic acid for bone metastases have similar efficacy and tolerability.</description><subject>Administration, Oral</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Bone cancer</subject><subject>Bone Density Conservation Agents - administration & dosage</subject><subject>Bone Neoplasms - drug therapy</subject><subject>Bone Neoplasms - secondary</subject><subject>Bone Resorption - drug therapy</subject><subject>Cancer Research</subject><subject>Clinical trials</subject><subject>Comparative studies</subject><subject>Diphosphonates - administration & dosage</subject><subject>Diseases of the osteoarticular system</subject><subject>Drug delivery systems</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Hematology</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Internal Medicine</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neoplasms - drug therapy</subject><subject>Oncology</subject><subject>Original Paper</subject><subject>Osteoporosis. Osteomalacia. Paget disease</subject><subject>Pharmacology. Drug treatments</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Quality of Life</subject><subject>Tumors of striated muscle and skeleton</subject><issn>0171-5216</issn><issn>1432-1335</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkU9rFTEUxYNY7Gv1A7iRINjdaP5OEneltCoUuqnrkGRuZMpM8kzySv325vEeFgRxleTmd-69h4PQW0o-UkLUp0qI4GwgRA9EUDM8vUAbuq9QzuVLtCFU0UEyOp6is1ofSH9LxV6hU6olESNlGxTvilvwI5S6q3hOrbhHSHl_9y5NJac5YBfm6TN2OOR168pcc8I54lbAtRVSw3nb5pwqjrngFZqrzbUu8zkBnuYKrsJrdBLdUuHN8TxH32-u76--Drd3X75dXd4OQXDSBs84F2ZiMXrJBY_eBcN8d-OjjMwYrRkYRhUIIpyGAErxCaSZqFaTjp6fo4tD323JP3dQm13nGmBZXILuyo5GUSEV_y9IjaR8HHUH3_8FPuRdSd2EZYxIokchO0QPUCi51gLRbsu8uvLLUmL3UdlDVLZHZfdR2aeueXdsvPMrTM-KYzYd-HAEXA1uicWlMNc_HCOacUVM59iBq_0r_YDyvOG_p_8GhQqstw</recordid><startdate>20081201</startdate><enddate>20081201</enddate><creator>Mystakidou, Kyriaki</creator><creator>Stathopoulou, Evangelia</creator><creator>Parpa, Efi</creator><creator>Kouloulias, Vassilios</creator><creator>Kouskouni, Evangelia</creator><creator>Vlahos, Lambros</creator><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7QP</scope><scope>7X8</scope></search><sort><creationdate>20081201</creationdate><title>Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease</title><author>Mystakidou, Kyriaki ; Stathopoulou, Evangelia ; Parpa, Efi ; Kouloulias, Vassilios ; Kouskouni, Evangelia ; Vlahos, Lambros</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c430t-b23349d2ffb5343fbac92b133bf5f299882e9217e404a8ece773de59d187d8fb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Administration, Oral</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Bone cancer</topic><topic>Bone Density Conservation Agents - administration & dosage</topic><topic>Bone Neoplasms - drug therapy</topic><topic>Bone Neoplasms - secondary</topic><topic>Bone Resorption - drug therapy</topic><topic>Cancer Research</topic><topic>Clinical trials</topic><topic>Comparative studies</topic><topic>Diphosphonates - administration & dosage</topic><topic>Diseases of the osteoarticular system</topic><topic>Drug delivery systems</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Hematology</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Internal Medicine</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neoplasms - drug therapy</topic><topic>Oncology</topic><topic>Original Paper</topic><topic>Osteoporosis. Osteomalacia. Paget disease</topic><topic>Pharmacology. Drug treatments</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Quality of Life</topic><topic>Tumors of striated muscle and skeleton</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mystakidou, Kyriaki</creatorcontrib><creatorcontrib>Stathopoulou, Evangelia</creatorcontrib><creatorcontrib>Parpa, Efi</creatorcontrib><creatorcontrib>Kouloulias, Vassilios</creatorcontrib><creatorcontrib>Kouskouni, Evangelia</creatorcontrib><creatorcontrib>Vlahos, Lambros</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cancer research and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mystakidou, Kyriaki</au><au>Stathopoulou, Evangelia</au><au>Parpa, Efi</au><au>Kouloulias, Vassilios</au><au>Kouskouni, Evangelia</au><au>Vlahos, Lambros</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease</atitle><jtitle>Journal of cancer research and clinical oncology</jtitle><stitle>J Cancer Res Clin Oncol</stitle><addtitle>J Cancer Res Clin Oncol</addtitle><date>2008-12-01</date><risdate>2008</risdate><volume>134</volume><issue>12</issue><spage>1303</spage><epage>1310</epage><pages>1303-1310</pages><issn>0171-5216</issn><eissn>1432-1335</eissn><coden>JCROD7</coden><abstract>Purpose
This trial is the first to compare directly the clinical response to and safety of oral and intravenous (IV) ibandronic acid for metastatic bone disease.
Methods
Patients ≥18 years with breast, prostate, lung, urogenital or colon cancer received IV ibandronic acid 6 mg infused over 15 min every 28 days or oral ibandronic acid 50 mg/day. Clinical response was determined using bone scintigraphy, radiography and serum C-terminal telopeptide of type I collagen (S-CTX) at months 3–6. Adverse events and biochemical safety measures were recorded.
Results
A total of 84.6 and 88.5% of patients had a complete/partial response to IV and oral ibandronic acid, respectively. Median percentage decreases in S-CTX were −39 and −35%, respectively. Bone pain scores decreased and analgesic use increased from month 0–3 and were stable from months 3–6. Both formulations improved physical and functioning scores.
Conclusion
Oral and IV ibandronic acid for bone metastases have similar efficacy and tolerability.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>18504612</pmid><doi>10.1007/s00432-008-0419-x</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0171-5216 |
| ispartof | Journal of cancer research and clinical oncology, 2008-12, Vol.134 (12), p.1303-1310 |
| issn | 0171-5216 1432-1335 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69714573 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Administration, Oral Aged Antineoplastic agents Biological and medical sciences Bone cancer Bone Density Conservation Agents - administration & dosage Bone Neoplasms - drug therapy Bone Neoplasms - secondary Bone Resorption - drug therapy Cancer Research Clinical trials Comparative studies Diphosphonates - administration & dosage Diseases of the osteoarticular system Drug delivery systems Drug therapy Female Hematology Humans Infusions, Intravenous Internal Medicine Male Medical sciences Medicine Medicine & Public Health Neoplasms - drug therapy Oncology Original Paper Osteoporosis. Osteomalacia. Paget disease Pharmacology. Drug treatments Prognosis Prospective Studies Quality of Life Tumors of striated muscle and skeleton |
| title | Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T08%3A38%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oral%20versus%20intravenous%20ibandronic%20acid:%20a%20comparison%20of%20treatment%20options%20for%20metastatic%20bone%20disease&rft.jtitle=Journal%20of%20cancer%20research%20and%20clinical%20oncology&rft.au=Mystakidou,%20Kyriaki&rft.date=2008-12-01&rft.volume=134&rft.issue=12&rft.spage=1303&rft.epage=1310&rft.pages=1303-1310&rft.issn=0171-5216&rft.eissn=1432-1335&rft.coden=JCROD7&rft_id=info:doi/10.1007/s00432-008-0419-x&rft_dat=%3Cproquest_cross%3E19513668%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=220508645&rft_id=info:pmid/18504612&rfr_iscdi=true |